Member Info for Jimzi

Looks like we a part of the wider summer selling. Many stocks hit on modest vol.
They may be right but I’m not gambling on being out when the news flow comes - see the AZN news price and out of the blue .
And there aren’t leaks, Rothschild sold at 70p and it went to £2 days later.

5p here and there is irrelevant with this minuscule free float .
Research always wins IMO

Well if its good enought for CC at 1.3 - good enough for me - added 10k DEC sb at 1.124.

From the Glycotest presentation

• Huge and growing populations with viral and non-viral hepatitis—driving progressive fibrosis, liver cancer risk and need for effective disease surveillance

o Cost effective HCC panel will enable early-stage HCC detection, lower cost treatment options, and better patient outcomes that will drive market adoption

• Estimated market value for the HCC Panel is $818 MM PA in the US alone
• Assumes only 620,000 US patients under surveillance—20% of 3.1 MM eligible patients

• In China…
• > 350,000 people die of liver cancer each year
• > 350MM people at risk for liver cancer due to serious liver disease—viral hepatitis, fatty liver disease and NASH, alcoholic liver disease and ASH

Top three liver disease countries are PRC, US and Japan. All three markets protected by patents – as is the EU.
So US market is $800m [above]
China has 5 times the US pop. Market size? Glyco receives 6% of gross sales – all net profit
Japan – half US pop – market size?
EU etc.

Run some figures based on the above with varying uptake at 55% GP [Edison] ex PRC which is full net profit on 6% gross sales for say 15 years [IPR protection is 20 years] and do you get a market capital of £10m?
Add one nought and its still very cheap, add two noughts is possible as it matures.

The cross holding with Fosan with the royalty is a masterstroke of accessing a huge market you otherwise would not penetrate. Proper management

No problem. I'll do reason 2 covering Glyco valuation ranges next week.

28 June : "representing a premium to our market value of 38%".

MV 17m
NAV 23.5m

Made up of
PDS 13.5m
Glyco 11m
Proaxis ZERO.

You miss the point - it has zero value in the NAV calc - and I am pointing out that Edison valued it at £15.6m in 2018. I am highlighting the difference between zero and £15.6m and news since.

CC did their own research obviously.

They spotted [ or were told wink] that Proaxis does not currently form part of their NAV calc as shown prior and referring to the August 5th RNS listing values [Big fat zero for Proaxis] – only PDS and Glyco have external value price reference points – MV and investment in respectfully.

Yet Edison seemed happy to value it in 2018 at £15.6m and that was before positive Neatstiks data, US distributor agreement and Geneva tie up [ which " This is an incredibly exciting addition to our product portfolio and fits with our business growth plans; including identifying and in-licensing diagnostic tools which fulfil a high unmet need"] .and AZN.

See exhibit 1

https://www.edisongroup.com/publication/steady-as-she-goes-5/22356/

It was trading at 70p pre AZN RNS and CC very happy paying £1.3 for 11% of the company post RNS – which crudely values the AZN deal at that date at £9m

So your are looking at Proaxis at an undemanding £25m or £1.25 per share and its not in the NAV , making it 150% of current mcap .not 40%

And given the miserly POS at 15%, any re-rate there in the light of AZN, well could be double up time.

All these condescending experts from on high can’t even handle a seller - it’s quite telling who to follow and who talks but buckles.

PDS is the soup.
Proaxis is the starter
Glyco is the main
Sofant, Sagetech and the other 12 investments are desert.

the price is dropping with buys

Very tetchy bb today

There are not more sellers than buyers.

Just one big seller [singular] feeding the ask and exiting

Who knows who or why. But is happens on many stocks.
If you sell cause someone else is selling fair enough - I want my Dimmies

Quite. Why some are still selling at 10% below what CC bought 11% at is beyond me.
They have just done your due diligence for free!

And they knew they are on to a winner when they read the August placing document - there is such a glaring clue Re Proaxis and Edison research note two years prior.[ and also SageTech]

The penny will drop in time.

It’s not a valid point. Don’t you understand that when the boss cooks up, the boys in black put a hold on everything to make sure there’s no political recourse- we are not talking money, it’s risk And most politicians are thick. - they know cameras and Mikes are everywhere in this country yet …..
Clinton’s prosecutor got done two years later for the same offence. Dumb.
So, they may think Han and cf are in a relationship. Etc were not talking sense
Politics

It’s not the amount , it’s the pr risk. Hence a possible recheck. You know what they are like if the spot light is on. Of course there is nothing to worry about but as today shows , human nature doesn’t follow logic

AVCT down 10.5% atm
We 7.5%

Everything is voltile as F. atm
AVCT -8%
SNG- 4%
GDR- 4%
Small US pharmas down 4% generally.
This bb is in a bubble.

Yep - it looks like there is a large seller who is not hanging around.

Induced shake or leak? Uncertainty eh!!

All a bit strange

alot of buys are Non protected portfolio - single protected transaction trades.

Although I have yet to find anyone who knows what it means - they ain't a PI trades

No rsp quote for over 6.5k shares to sell - still 9.4p to buy 250k.
Shops basically shut for any sig trade. Who knows why

We know we are at the bottom but could be a long summer!! Who cares.

Buy and sell price the same on min vol - something going on - dunno what